Free and total insulin-like growth factor (IGF)-I, -II, and IGF binding protein-1, -2, and -3 serum levels in patients with active thyroid eye disease

被引:80
作者
Krassas, GE
Pontikides, N
Kaltsas, T
Dumas, A
Frystyk, J
Chen, JW
Flyvbjerg, A
机构
[1] Panagia Gen Hosp, Dept Endocrinol & Metab, Thessaloniki 55132, Greece
[2] Nucl Med Ctr, Thessaloniki 54622, Greece
[3] Aarhus Univ Hosp, Aarhus Kommune Hosp, Aarhus Ctr, Med Res Labs, DK-8000 Aarhus, Denmark
关键词
D O I
10.1210/jc.2002-021349
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To determine whether serum levels of total (T) and free (F) IGF-I and -II and IGF binding protein (IGFBP),-1, -2, and -3 are normal in euthyroid patients with Graves' disease and active thyroid ophthalmopathy, we investigated the above mentioned parameters in 21 patients (11 male, 10 female) aged 50.8 +/- 11.8 yr (range 35-70) and 19 healthy individuals matched for age, gender, and body mass index. All patients had active thyroid eye disease (TED) with clinical activity scores A and positive orbital octreoscan in both eyes. Serum T and F IGF-I and IGF-II were determined using noncompetitive time-resolved monoclonal immunofluorometric assays, IGFBP-1 was determined by an in-house RIA, IGFBP-2 by a novel in-house time-resolved immunofluorometric assay, whereas IGFBP-3 by an immunoradiometric assay. All data are expressed as mean +/- SD. Our results show that T and F IGF-I, -II, and IGFBP-1, -2, and -3 levels in patients were similar to controls and did not show any significant difference. Specifically, mean T IGF-I for patients group was 131 (61), F IGF-I was 0.47 (0.16), T IGF-II was 1056 (300), F IGF-II was 1.45 (0.54), IGFBP-I was 33 (14), IGFBP-2 was 848 (377), and finally IGFBP-3 was 3953 (1422). For controls, mean T IGF-I was 146 (51), FlGF-I was 0.85 (0.43), TIGF-II was 939 (197), F IGF-II was 1.53 (0.53), IGFBP-1 was 44 (24), IGFBP-2 was 764 (316) and finally IGFBP-3 was 3721 (1017). Furthermore, no statistically differences emerged in the ratio between molar weights of T IGF-I/IGFBP-3 and T IGF-I/IGFBP-3, as well as to the F/T IGF-I and F/TIGF-II. Finally, no relationship was found between the levels of the above-mentioned parameters and clinical activity scores, octreoscan scores, and thyroid hormones. Our data demonstrate for the first time that serum levels of IGFs (including free fractions) and IGFBPs are not increased in euthyroid Graves' patients with active TED. The increased lGF levels in retrobulbar tissues previously described, appear to be independent of serum IGFs concentration and probably represent autocrine and/or paracrine activity.
引用
收藏
页码:132 / 135
页数:4
相关论文
共 33 条
  • [1] BAHN RS, 1993, NEW ENGL J MED, V329, P1468
  • [2] Cytokines in thyroid eye disease: Potential for anticytokine therapy
    Bahn, RS
    [J]. THYROID, 1998, 8 (05) : 415 - 418
  • [3] Management of Graves' ophthalmopathy: Reality and perspectives
    Bartalena, L
    Pinchera, A
    Marcocci, C
    [J]. ENDOCRINE REVIEWS, 2000, 21 (02) : 168 - 199
  • [4] GRAVES OPHTHALMOPATHY - CURRENT CONCEPTS REGARDING PATHOGENESIS AND MANAGEMENT
    BURCH, HB
    WARTOFSKY, L
    [J]. ENDOCRINE REVIEWS, 1993, 14 (06) : 747 - 793
  • [5] OCTREOTIDE AND GRAVES OPHTHALMOPATHY AND PRETIBIAL MYXEDEMA
    CHANG, TC
    KAO, SCS
    HUANG, KM
    [J]. BRITISH MEDICAL JOURNAL, 1992, 304 (6820) : 158 - 158
  • [6] FREE INSULIN-LIKE GROWTH-FACTORS (IGF-I AND IGF-II) IN HUMAN SERUM
    FRYSTYK, J
    SKJAERBAEK, C
    DINESEN, B
    ORSKOV, H
    [J]. FEBS LETTERS, 1994, 348 (02) : 185 - 191
  • [7] Frystyk J, 1995, GROWTH REGULAT, V5, P169
  • [8] HANSSON HA, 1986, LANCET, V1, P218
  • [9] Hansson HA, 1989, ACTA ENDOCR-COP S2, V21, P107
  • [10] PATHOGENESIS OF GRAVES OPHTHALMOPATHY - RECENT CONTROVERSIES AND PROGRESS
    HEUFELDER, AE
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1995, 132 (05) : 532 - 541